← All Exelixis, INC filings

Exelixis, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
EXEL
Exelixis, INC
DEF: Exelixis 2026 Proxy Statement Analysis
Exelixis, Inc. filed its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase equity plan shares.
NASDAQ
EXEL
Exelixis, INC
DEFA14A: Exelixis, Inc. Files Definitive Proxy Statement with SEC
Exelixis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
EXEL
Exelixis, INC
DEF: Exelixis Reports Strong 2024 Performance and Outlines 2025 Priorities
Exelixis reports a productive 2024 with cabozantinib franchise growth and advancements in zanzalintinib development, setting the stage for multiple pivotal data readouts in 2025.
NASDAQ
EXEL
Exelixis, INC
DEFA14A: Exelixis, Inc. Files Definitive Proxy Statement with SEC
Exelixis, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
EXEL
Exelixis, INC
DEF 14A: Exelixis Aims to Boost Shareholder Value with Strategic R&D Focus and $1 Billion Buyback Program
Exelixis is focused on improving cancer care and creating shareholder value through strategic R&D investments and a $1 billion share repurchase program.